Astrazeneca shows megamergers were still possible in 2020
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Agios gets $1.8bn and a new focus
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 – Forma gets an early edge over Agios in sickle cell disease
And both companies’ pyruvate kinase R activators could have Global Blood looking over its shoulder, though pain crises sow doubts.
Agios gets a pre-Ash boost
Mitapivat's pivotal win in a rare type of anaemia could bode well for its chances in thalassaemia and sickle cell disease.
Ash 2020 preview – late-breaker puts Uniqure in pole position
Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.
